ATE323686T1 - Substituierte 2-arylbenzazole und ihre verwendung als antitumorale mittel - Google Patents

Substituierte 2-arylbenzazole und ihre verwendung als antitumorale mittel

Info

Publication number
ATE323686T1
ATE323686T1 AT00954726T AT00954726T ATE323686T1 AT E323686 T1 ATE323686 T1 AT E323686T1 AT 00954726 T AT00954726 T AT 00954726T AT 00954726 T AT00954726 T AT 00954726T AT E323686 T1 ATE323686 T1 AT E323686T1
Authority
AT
Austria
Prior art keywords
substituted
arylbenzazoles
amino acid
substituent
antitumoral agents
Prior art date
Application number
AT00954726T
Other languages
English (en)
Inventor
Malcolm Francis Graham Stevens
Tracey Dawn Poole
Andrew David Westwell
Ian Paul Hutchinson
Mei-Sze Chua
Original Assignee
Cancer Res Ventures Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Res Ventures Ltd filed Critical Cancer Res Ventures Ltd
Application granted granted Critical
Publication of ATE323686T1 publication Critical patent/ATE323686T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22—Tin compounds
    • C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT00954726T 1999-08-20 2000-08-21 Substituierte 2-arylbenzazole und ihre verwendung als antitumorale mittel ATE323686T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9919673.5A GB9919673D0 (en) 1999-08-20 1999-08-20 2-Arlybenzazole compounds

Publications (1)

Publication Number Publication Date
ATE323686T1 true ATE323686T1 (de) 2006-05-15

Family

ID=10859458

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00954726T ATE323686T1 (de) 1999-08-20 2000-08-21 Substituierte 2-arylbenzazole und ihre verwendung als antitumorale mittel

Country Status (13)

Country Link
US (1) US6858633B1 (de)
EP (1) EP1204650B1 (de)
JP (1) JP2003507462A (de)
AT (1) ATE323686T1 (de)
AU (1) AU783360B2 (de)
CA (1) CA2382406C (de)
CY (1) CY1105091T1 (de)
DE (1) DE60027435T2 (de)
DK (1) DK1204650T3 (de)
ES (1) ES2263483T3 (de)
GB (1) GB9919673D0 (de)
PT (1) PT1204650E (de)
WO (1) WO2001014354A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7270800B2 (en) 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
SI1334091T1 (sl) * 2000-08-24 2013-01-31 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Derivati tioflavina in njihova uporaba pri diagnozi in terapiji pri Alzheimerjevi bolezni
CA2474411A1 (en) * 2002-02-13 2003-08-21 Amersham Plc Benzothiazole derivatives for in vivo imaging of amyloid plaques
EP1517974A1 (de) * 2002-07-01 2005-03-30 MERCK PATENT GmbH Polymerisierbare lumineszenzverbindungen und mischungen, lumineszenzpolymermaterialien und deren verwendung
CN101413143B (zh) 2002-12-19 2013-09-18 斯克里普斯研究学院 稳定甲状腺素运载蛋白和抑制甲状腺素运载蛋白错折叠的组合物和方法
GB0229686D0 (en) 2002-12-20 2003-01-29 Amersham Plc Solid-phase fluorination of benzothiazoles
ES2393921T3 (es) * 2003-03-14 2013-01-02 University Of Pittsburgh - Of The Commonwealthsystem Of Higher Education Compuestos derivados de BENZOTIAZOL, composiciones y usos
CA2438032C (en) * 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
US8236282B2 (en) 2003-08-22 2012-08-07 University of Pittsburgh—of the Commonwealth System of Higher Education Benzothiazole derivative compounds, compositions and uses
AU2005245470A1 (en) 2004-05-20 2005-12-01 Foldrx Pharmaceuticals, Inc. 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
CA2627722A1 (en) 2005-10-31 2007-06-21 Merck & Co., Inc. Cetp inhibitors
WO2007124345A2 (en) * 2006-04-21 2007-11-01 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Beta-amyloid pet imaging agents
AU2008266957A1 (en) 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. CETP inhibitors derived from benzoxazole arylamides
US8445480B2 (en) 2007-06-20 2013-05-21 Merck Sharp & Dohme Corp. CETP inhibitors derived from benzoxazole arylamides
AU2008266956A1 (en) 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. CETP inhibitors derived from benzoxazole arylamides
CN101790387B (zh) * 2007-08-30 2013-03-20 通用电气健康护理有限公司 放射性药物组合物
US9259495B2 (en) * 2010-10-12 2016-02-16 Mayo Foundation For Medical Education And Research Imaging of meningiomas using phenylbenzothiazole, stilbene, or biphenylalkyne derivatives
US8592603B2 (en) * 2011-02-22 2013-11-26 Kaohsiung Medical University Synthesis of 2-(4-aminophenyl) benzothiazole derivatives and use thereof
WO2013038351A1 (en) 2011-09-16 2013-03-21 Pfizer Inc. Solid forms of a transthyretin dissociation inhibitor
US20150157744A1 (en) 2012-06-27 2015-06-11 Geoffrey B. Johnson Treatment of meningiomas using phenylbenzothiazole, stilbene, biphenylalkyne, or pyridine derivatives
EP2940002B1 (de) * 2012-12-25 2016-12-14 Nippon Soda Co., Ltd. Halogeniertes anilin und verfahren zur herstellung davon
WO2015127548A1 (en) * 2014-02-28 2015-09-03 The Royal Institution For The Advancement Of Learning / Mcgill University Tc-ptp inhibitors as apc activators for immunotherapy
EP3296294B1 (de) * 2015-05-09 2020-02-12 Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd Verfahren zur behandlung oder prävention von brustkrebs
CN111166744B (zh) * 2018-11-12 2024-06-25 诺丁汉大学 4-(苯并噻唑-2-基)芳胺类化合物治疗胃癌的用途
CN111170963B (zh) * 2018-11-12 2023-05-23 江苏新元素医药科技有限公司 4-(苯并硒唑-2-基)芳胺类化合物治疗胃癌的用途
CN111170962B (zh) * 2018-11-12 2023-05-23 江苏新元素医药科技有限公司 4-(苯并硒唑-2-基)芳胺类化合物治疗肠癌的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL242547A (de) 1958-08-22
US3401048A (en) 1964-06-22 1968-09-10 Mitsui Kagaku Kogyo Kabushiki 2-styrylazole optical brightener
DE2333378A1 (de) 1973-06-30 1975-01-23 Basf Ag Neue verbindungen der benzoxazol- und der benzthiazolreihe und farbbildner fuer kopierverfahren
GB9317949D0 (en) * 1993-08-28 1993-10-13 Stevens Malcolm F G Benzothiazole compounds
GB9503946D0 (en) 1995-02-28 1995-04-19 Cancer Res Campaign Tech Benzazole compounds
JPH1160573A (ja) * 1997-08-22 1999-03-02 Nippon Kayaku Co Ltd トリアジン誘導体及びテロメラーゼ阻害剤

Also Published As

Publication number Publication date
EP1204650B1 (de) 2006-04-19
DK1204650T3 (da) 2006-08-21
JP2003507462A (ja) 2003-02-25
EP1204650A1 (de) 2002-05-15
AU6708500A (en) 2001-03-19
CA2382406A1 (en) 2001-03-01
CA2382406C (en) 2009-05-19
DE60027435D1 (de) 2006-05-24
GB9919673D0 (en) 1999-10-20
US6858633B1 (en) 2005-02-22
PT1204650E (pt) 2006-08-31
CY1105091T1 (el) 2009-11-04
DE60027435T2 (de) 2007-04-19
AU783360B2 (en) 2005-10-20
WO2001014354A1 (en) 2001-03-01
ES2263483T3 (es) 2006-12-16

Similar Documents

Publication Publication Date Title
ATE323686T1 (de) Substituierte 2-arylbenzazole und ihre verwendung als antitumorale mittel
AU2003301020A8 (en) Isoquinolinone derivatives and their use as therapeutic agents
DE69823843D1 (de) Benzimidazolinone, benzoxazolinone, benzopiperazinone, indanone und deren derivate als faktor xa inhibitoren
DE69926806D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
TR199800436A2 (xx) Primidin t�revlerinin kanserin �nlenmesi i�in kullan�lmas�.
TR200102800T2 (tr) Yeni bileşikler.
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
YU69902A (sh) Novi derivati piperazina
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
DK0623607T3 (da) Benzofuranyl- og -thiophenyl-alkancarboxylsyrederivater
DE60015594D1 (de) Imidazolderivate und deren verwendung als raf kinase inhibitoren
ATE251613T1 (de) Pyrimidinonderivate zur behandlung von atheroscleros
MX2007000028A (es) Derivados de nicotinamida y su uso como agentes terapeuticos.
TR200201638T2 (tr) Yeni imidazo[1,3,5]triazinonlar ve kullanımları
DE60045508D1 (de) Dalda-analoge und ihre verwendung
ATE248897T1 (de) Anthrachinonverbindungen und ihre derivate
BR0115121A (pt) Compostos n-((1,2,4)triazoloazinil)tiofenossulfonamida como herbicidas
ATE277010T1 (de) Bis-indolederivate und ihre verwendung als entzündungshemmende mittel
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
PT1098885E (pt) Compostos de imidazole e sua utilizacao como inibidores da desaminase de adenosina
DE69414194D1 (de) Aminosäurederivate und ihre Verwendung als Enkephalinase-Inhibitoren
TR200001941T1 (tr) TNF ve PDE-IV önleyici aktiviteye sahip heterosiklik bileşiklerin N-oksitleri.
DE60227113D1 (de) Kondensierte camptothecine als antitumormittel
ATE239721T1 (de) Zimtsäure-derivate als zelladhäsions-moleküle
NO20004075L (no) Substituerte pyrimidin-2-yloksy-karboksylsyrederivater, fremstilling av disse og deres anvendelse som endotelin- antagonister

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1204650

Country of ref document: EP